nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—Cytochrome P450 2C9 Inhibitors—Efavirenz—acquired immunodeficiency syndrome	0.54	1	CiPCiCtD
Regorafenib—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0355	0.115	CbGbCtD
Regorafenib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0105	0.0342	CbGbCtD
Regorafenib—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0104	0.0338	CbGbCtD
Regorafenib—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.00977	0.0318	CbGbCtD
Regorafenib—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.00977	0.0318	CbGbCtD
Regorafenib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.00952	0.031	CbGbCtD
Regorafenib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.00952	0.031	CbGbCtD
Regorafenib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.00913	0.0297	CbGbCtD
Regorafenib—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.00884	0.0287	CbGbCtD
Regorafenib—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.00741	0.0241	CbGbCtD
Regorafenib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00706	0.023	CbGbCtD
Regorafenib—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0067	0.0218	CbGbCtD
Regorafenib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00669	0.0218	CbGbCtD
Regorafenib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00669	0.0218	CbGbCtD
Regorafenib—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.00661	0.0215	CbGbCtD
Regorafenib—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.00621	0.0202	CbGbCtD
Regorafenib—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00562	0.0183	CbGbCtD
Regorafenib—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00562	0.0183	CbGbCtD
Regorafenib—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00549	0.0179	CbGbCtD
Regorafenib—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00516	0.0168	CbGbCtD
Regorafenib—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00516	0.0168	CbGbCtD
Regorafenib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00507	0.0165	CbGbCtD
Regorafenib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00507	0.0165	CbGbCtD
Regorafenib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00501	0.0163	CbGbCtD
Regorafenib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00486	0.0158	CbGbCtD
Regorafenib—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00485	0.0158	CbGbCtD
Regorafenib—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00471	0.0153	CbGbCtD
Regorafenib—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00467	0.0152	CbGbCtD
Regorafenib—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00467	0.0152	CbGbCtD
Regorafenib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00453	0.0147	CbGbCtD
Regorafenib—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00426	0.0138	CbGbCtD
Regorafenib—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00426	0.0138	CbGbCtD
Regorafenib—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00408	0.0133	CbGbCtD
Regorafenib—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00403	0.0131	CbGbCtD
Regorafenib—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00391	0.0127	CbGbCtD
Regorafenib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00391	0.0127	CbGbCtD
Regorafenib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0038	0.0123	CbGbCtD
Regorafenib—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00354	0.0115	CbGbCtD
Regorafenib—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00354	0.0115	CbGbCtD
Regorafenib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00343	0.0112	CbGbCtD
Regorafenib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00343	0.0112	CbGbCtD
Regorafenib—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00339	0.011	CbGbCtD
Regorafenib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00329	0.0107	CbGbCtD
Regorafenib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00319	0.0104	CbGbCtD
Regorafenib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.003	0.00976	CbGbCtD
Regorafenib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.003	0.00976	CbGbCtD
Regorafenib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00272	0.00883	CbGbCtD
Regorafenib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00272	0.00883	CbGbCtD
Regorafenib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00255	0.00828	CbGbCtD
Regorafenib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00234	0.00762	CbGbCtD
Regorafenib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00228	0.0074	CbGbCtD
Regorafenib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00206	0.00669	CbGbCtD
Regorafenib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00206	0.00669	CbGbCtD
Regorafenib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00197	0.00641	CbGbCtD
Regorafenib—FLT4—endothelium—acquired immunodeficiency syndrome	0.000913	0.02	CbGeAlD
Regorafenib—TEK—endothelium—acquired immunodeficiency syndrome	0.000735	0.0161	CbGeAlD
Regorafenib—DDR2—retina—acquired immunodeficiency syndrome	0.000729	0.016	CbGeAlD
Regorafenib—FLT1—endothelium—acquired immunodeficiency syndrome	0.00071	0.0156	CbGeAlD
Regorafenib—DDR2—skin of body—acquired immunodeficiency syndrome	0.00064	0.014	CbGeAlD
Regorafenib—FLT1—blood plasma—acquired immunodeficiency syndrome	0.000631	0.0138	CbGeAlD
Regorafenib—KDR—endothelium—acquired immunodeficiency syndrome	0.0006	0.0132	CbGeAlD
Regorafenib—FRK—lymphoid tissue—acquired immunodeficiency syndrome	0.000578	0.0127	CbGeAlD
Regorafenib—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.000564	0.0124	CbGeAlD
Regorafenib—KDR—blood plasma—acquired immunodeficiency syndrome	0.000533	0.0117	CbGeAlD
Regorafenib—KIT—endothelium—acquired immunodeficiency syndrome	0.000532	0.0117	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—acquired immunodeficiency syndrome	0.000518	0.0114	CbGeAlD
Regorafenib—DDR2—digestive system—acquired immunodeficiency syndrome	0.000512	0.0112	CbGeAlD
Regorafenib—EPHX2—retina—acquired immunodeficiency syndrome	0.000493	0.0108	CbGeAlD
Regorafenib—KIT—blood plasma—acquired immunodeficiency syndrome	0.000473	0.0104	CbGeAlD
Regorafenib—DDR2—spinal cord—acquired immunodeficiency syndrome	0.00047	0.0103	CbGeAlD
Regorafenib—DDR2—vagina—acquired immunodeficiency syndrome	0.000452	0.00992	CbGeAlD
Regorafenib—DDR2—lung—acquired immunodeficiency syndrome	0.000428	0.00938	CbGeAlD
Regorafenib—DDR2—nervous system—acquired immunodeficiency syndrome	0.000396	0.00869	CbGeAlD
Regorafenib—DDR2—central nervous system—acquired immunodeficiency syndrome	0.000381	0.00836	CbGeAlD
Regorafenib—MAPK11—nervous system—acquired immunodeficiency syndrome	0.000375	0.00824	CbGeAlD
Regorafenib—MAPK11—central nervous system—acquired immunodeficiency syndrome	0.000361	0.00793	CbGeAlD
Regorafenib—FLT1—retina—acquired immunodeficiency syndrome	0.000345	0.00758	CbGeAlD
Regorafenib—BRAF—blood—acquired immunodeficiency syndrome	0.000345	0.00756	CbGeAlD
Regorafenib—BRAF—bone marrow—acquired immunodeficiency syndrome	0.000334	0.00732	CbGeAlD
Regorafenib—EPHX2—blood—acquired immunodeficiency syndrome	0.00033	0.00723	CbGeAlD
Regorafenib—FGFR2—skin of body—acquired immunodeficiency syndrome	0.000327	0.00718	CbGeAlD
Regorafenib—BRAF—vagina—acquired immunodeficiency syndrome	0.00032	0.00701	CbGeAlD
Regorafenib—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.000316	0.00694	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—acquired immunodeficiency syndrome	0.000316	0.00693	CbGeAlD
Regorafenib—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000306	0.0067	CbGeAlD
Regorafenib—EPHX2—vagina—acquired immunodeficiency syndrome	0.000305	0.0067	CbGeAlD
Regorafenib—DDR2—brain—acquired immunodeficiency syndrome	0.000303	0.00664	CbGeAlD
Regorafenib—BRAF—lung—acquired immunodeficiency syndrome	0.000302	0.00663	CbGeAlD
Regorafenib—RAF1—skin of body—acquired immunodeficiency syndrome	0.000301	0.00661	CbGeAlD
Regorafenib—FLT4—blood—acquired immunodeficiency syndrome	0.000297	0.00652	CbGeAlD
Regorafenib—DDR2—lymph node—acquired immunodeficiency syndrome	0.000292	0.00642	CbGeAlD
Regorafenib—KDR—retina—acquired immunodeficiency syndrome	0.000292	0.00641	CbGeAlD
Regorafenib—EPHX2—lung—acquired immunodeficiency syndrome	0.000289	0.00634	CbGeAlD
Regorafenib—FLT4—bone marrow—acquired immunodeficiency syndrome	0.000288	0.00631	CbGeAlD
Regorafenib—MAPK11—brain—acquired immunodeficiency syndrome	0.000287	0.00629	CbGeAlD
Regorafenib—FGFR1—spinal cord—acquired immunodeficiency syndrome	0.000282	0.0062	CbGeAlD
Regorafenib—RET—lymphoid tissue—acquired immunodeficiency syndrome	0.000279	0.00612	CbGeAlD
Regorafenib—MAPK11—lymph node—acquired immunodeficiency syndrome	0.000277	0.00608	CbGeAlD
Regorafenib—RET—digestive system—acquired immunodeficiency syndrome	0.000275	0.00604	CbGeAlD
Regorafenib—FGFR1—vagina—acquired immunodeficiency syndrome	0.000272	0.00596	CbGeAlD
Regorafenib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000267	0.00585	CbGeAlD
Regorafenib—RET—blood—acquired immunodeficiency syndrome	0.000262	0.00576	CbGeAlD
Regorafenib—FGFR2—digestive system—acquired immunodeficiency syndrome	0.000262	0.00574	CbGeAlD
Regorafenib—FLT4—lung—acquired immunodeficiency syndrome	0.000261	0.00571	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—acquired immunodeficiency syndrome	0.00026	0.00571	CbGeAlD
Regorafenib—EPHA2—digestive system—acquired immunodeficiency syndrome	0.000257	0.00564	CbGeAlD
Regorafenib—FGFR1—lung—acquired immunodeficiency syndrome	0.000257	0.00564	CbGeAlD
Regorafenib—TEK—lymphoid tissue—acquired immunodeficiency syndrome	0.000254	0.00557	CbGeAlD
Regorafenib—RET—spinal cord—acquired immunodeficiency syndrome	0.000253	0.00554	CbGeAlD
Regorafenib—FGFR2—blood—acquired immunodeficiency syndrome	0.000249	0.00547	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—acquired immunodeficiency syndrome	0.000246	0.00539	CbGeAlD
Regorafenib—EPHA2—blood—acquired immunodeficiency syndrome	0.000245	0.00537	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—acquired immunodeficiency syndrome	0.000244	0.00535	CbGeAlD
Regorafenib—FLT1—digestive system—acquired immunodeficiency syndrome	0.000243	0.00532	CbGeAlD
Regorafenib—RAF1—digestive system—acquired immunodeficiency syndrome	0.000241	0.00529	CbGeAlD
Regorafenib—FGFR2—spinal cord—acquired immunodeficiency syndrome	0.00024	0.00527	CbGeAlD
Regorafenib—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000239	0.00525	CbGeAlD
Regorafenib—TEK—blood—acquired immunodeficiency syndrome	0.000239	0.00524	CbGeAlD
Regorafenib—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000237	0.0052	CbGeAlD
Regorafenib—FLT1—blood—acquired immunodeficiency syndrome	0.000231	0.00507	CbGeAlD
Regorafenib—TEK—spinal cord—acquired immunodeficiency syndrome	0.00023	0.00505	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.00023	0.00505	CbGeAlD
Regorafenib—RAF1—blood—acquired immunodeficiency syndrome	0.00023	0.00504	CbGeAlD
Regorafenib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000227	0.00499	CbGeAlD
Regorafenib—KIT—skin of body—acquired immunodeficiency syndrome	0.000227	0.00498	CbGeAlD
Regorafenib—EPHA2—vagina—acquired immunodeficiency syndrome	0.000227	0.00498	CbGeAlD
Regorafenib—ABL1—retina—acquired immunodeficiency syndrome	0.000225	0.00494	CbGeAlD
Regorafenib—FLT1—spinal cord—acquired immunodeficiency syndrome	0.000223	0.00488	CbGeAlD
Regorafenib—RAF1—bone marrow—acquired immunodeficiency syndrome	0.000222	0.00488	CbGeAlD
Regorafenib—PDGFRB—skin of body—acquired immunodeficiency syndrome	0.000222	0.00487	CbGeAlD
Regorafenib—RAF1—spinal cord—acquired immunodeficiency syndrome	0.000221	0.00485	CbGeAlD
Regorafenib—FGFR2—lung—acquired immunodeficiency syndrome	0.000219	0.00479	CbGeAlD
Regorafenib—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000217	0.00476	CbGeAlD
Regorafenib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000217	0.00475	CbGeAlD
Regorafenib—EPHA2—lung—acquired immunodeficiency syndrome	0.000215	0.00471	CbGeAlD
Regorafenib—FLT1—vagina—acquired immunodeficiency syndrome	0.000214	0.0047	CbGeAlD
Regorafenib—BRAF—brain—acquired immunodeficiency syndrome	0.000214	0.00469	CbGeAlD
Regorafenib—RET—nervous system—acquired immunodeficiency syndrome	0.000213	0.00467	CbGeAlD
Regorafenib—RAF1—vagina—acquired immunodeficiency syndrome	0.000213	0.00467	CbGeAlD
Regorafenib—TEK—lung—acquired immunodeficiency syndrome	0.00021	0.0046	CbGeAlD
Regorafenib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000209	0.00458	CbGeAlD
Regorafenib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000208	0.00455	CbGeAlD
Regorafenib—BRAF—lymph node—acquired immunodeficiency syndrome	0.000207	0.00453	CbGeAlD
Regorafenib—UGT1A1—blood—acquired immunodeficiency syndrome	0.000207	0.00453	CbGeAlD
Regorafenib—RET—central nervous system—acquired immunodeficiency syndrome	0.000205	0.0045	CbGeAlD
Regorafenib—KDR—digestive system—acquired immunodeficiency syndrome	0.000205	0.0045	CbGeAlD
Regorafenib—EPHX2—brain—acquired immunodeficiency syndrome	0.000204	0.00449	CbGeAlD
Regorafenib—FLT1—lung—acquired immunodeficiency syndrome	0.000203	0.00444	CbGeAlD
Regorafenib—FGFR2—nervous system—acquired immunodeficiency syndrome	0.000202	0.00444	CbGeAlD
Regorafenib—RAF1—lung—acquired immunodeficiency syndrome	0.000201	0.00442	CbGeAlD
Regorafenib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.000201	0.0044	CbGeAlD
Regorafenib—EPHA2—nervous system—acquired immunodeficiency syndrome	0.000199	0.00436	CbGeAlD
Regorafenib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000198	0.00434	CbGeAlD
Regorafenib—EPHX2—lymph node—acquired immunodeficiency syndrome	0.000198	0.00433	CbGeAlD
Regorafenib—KDR—blood—acquired immunodeficiency syndrome	0.000195	0.00428	CbGeAlD
Regorafenib—FGFR2—central nervous system—acquired immunodeficiency syndrome	0.000195	0.00427	CbGeAlD
Regorafenib—TEK—nervous system—acquired immunodeficiency syndrome	0.000194	0.00426	CbGeAlD
Regorafenib—EPHA2—central nervous system—acquired immunodeficiency syndrome	0.000191	0.0042	CbGeAlD
Regorafenib—PDGFRA—lung—acquired immunodeficiency syndrome	0.00019	0.00416	CbGeAlD
Regorafenib—KDR—bone marrow—acquired immunodeficiency syndrome	0.000189	0.00415	CbGeAlD
Regorafenib—KDR—spinal cord—acquired immunodeficiency syndrome	0.000188	0.00413	CbGeAlD
Regorafenib—FLT1—nervous system—acquired immunodeficiency syndrome	0.000188	0.00411	CbGeAlD
Regorafenib—TEK—central nervous system—acquired immunodeficiency syndrome	0.000187	0.0041	CbGeAlD
Regorafenib—RAF1—nervous system—acquired immunodeficiency syndrome	0.000186	0.00409	CbGeAlD
Regorafenib—FLT4—brain—acquired immunodeficiency syndrome	0.000184	0.00405	CbGeAlD
Regorafenib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000184	0.00403	CbGeAlD
Regorafenib—FGFR1—brain—acquired immunodeficiency syndrome	0.000182	0.00399	CbGeAlD
Regorafenib—KIT—digestive system—acquired immunodeficiency syndrome	0.000182	0.00399	CbGeAlD
Regorafenib—KDR—vagina—acquired immunodeficiency syndrome	0.000181	0.00397	CbGeAlD
Regorafenib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000181	0.00396	CbGeAlD
Regorafenib—FLT1—central nervous system—acquired immunodeficiency syndrome	0.000181	0.00396	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—acquired immunodeficiency syndrome	0.00018	0.00394	CbGeAlD
Regorafenib—RAF1—central nervous system—acquired immunodeficiency syndrome	0.00018	0.00394	CbGeAlD
Regorafenib—FLT4—lymph node—acquired immunodeficiency syndrome	0.000178	0.00391	CbGeAlD
Regorafenib—PDGFRB—digestive system—acquired immunodeficiency syndrome	0.000177	0.00389	CbGeAlD
Regorafenib—FGFR1—lymph node—acquired immunodeficiency syndrome	0.000176	0.00386	CbGeAlD
Regorafenib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000176	0.00386	CbGeAlD
Regorafenib—KIT—blood—acquired immunodeficiency syndrome	0.000173	0.0038	CbGeAlD
Regorafenib—KDR—lung—acquired immunodeficiency syndrome	0.000171	0.00376	CbGeAlD
Regorafenib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000169	0.00371	CbGeAlD
Regorafenib—PDGFRB—blood—acquired immunodeficiency syndrome	0.000169	0.00371	CbGeAlD
Regorafenib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000167	0.00367	CbGeAlD
Regorafenib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000167	0.00366	CbGeAlD
Regorafenib—PDGFRB—bone marrow—acquired immunodeficiency syndrome	0.000164	0.00359	CbGeAlD
Regorafenib—PDGFRB—spinal cord—acquired immunodeficiency syndrome	0.000163	0.00357	CbGeAlD
Regorafenib—RET—brain—acquired immunodeficiency syndrome	0.000163	0.00357	CbGeAlD
Regorafenib—KIT—vagina—acquired immunodeficiency syndrome	0.00016	0.00352	CbGeAlD
Regorafenib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.00016	0.00351	CbGeAlD
Regorafenib—KDR—nervous system—acquired immunodeficiency syndrome	0.000159	0.00348	CbGeAlD
Regorafenib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000158	0.00347	CbGeAlD
Regorafenib—RET—lymph node—acquired immunodeficiency syndrome	0.000157	0.00345	CbGeAlD
Regorafenib—PDGFRB—vagina—acquired immunodeficiency syndrome	0.000157	0.00344	CbGeAlD
Regorafenib—FGFR2—brain—acquired immunodeficiency syndrome	0.000155	0.00339	CbGeAlD
Regorafenib—KDR—central nervous system—acquired immunodeficiency syndrome	0.000153	0.00335	CbGeAlD
Regorafenib—EPHA2—brain—acquired immunodeficiency syndrome	0.000152	0.00333	CbGeAlD
Regorafenib—KIT—lung—acquired immunodeficiency syndrome	0.000152	0.00333	CbGeAlD
Regorafenib—ABL1—blood—acquired immunodeficiency syndrome	0.000151	0.00331	CbGeAlD
Regorafenib—TEK—brain—acquired immunodeficiency syndrome	0.000148	0.00325	CbGeAlD
Regorafenib—PDGFRB—lung—acquired immunodeficiency syndrome	0.000148	0.00325	CbGeAlD
Regorafenib—EPHA2—lymph node—acquired immunodeficiency syndrome	0.000147	0.00322	CbGeAlD
Regorafenib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000146	0.0032	CbGeAlD
Regorafenib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000145	0.00318	CbGeAlD
Regorafenib—FLT1—brain—acquired immunodeficiency syndrome	0.000143	0.00315	CbGeAlD
Regorafenib—TEK—lymph node—acquired immunodeficiency syndrome	0.000143	0.00314	CbGeAlD
Regorafenib—RAF1—brain—acquired immunodeficiency syndrome	0.000143	0.00313	CbGeAlD
Regorafenib—KIT—nervous system—acquired immunodeficiency syndrome	0.000141	0.00308	CbGeAlD
Regorafenib—ABL1—vagina—acquired immunodeficiency syndrome	0.00014	0.00306	CbGeAlD
Regorafenib—FLT1—lymph node—acquired immunodeficiency syndrome	0.000139	0.00304	CbGeAlD
Regorafenib—RAF1—lymph node—acquired immunodeficiency syndrome	0.000138	0.00302	CbGeAlD
Regorafenib—PDGFRB—nervous system—acquired immunodeficiency syndrome	0.000137	0.00301	CbGeAlD
Regorafenib—KIT—central nervous system—acquired immunodeficiency syndrome	0.000135	0.00297	CbGeAlD
Regorafenib—PDGFRA—brain—acquired immunodeficiency syndrome	0.000134	0.00295	CbGeAlD
Regorafenib—PDGFRB—central nervous system—acquired immunodeficiency syndrome	0.000132	0.0029	CbGeAlD
Regorafenib—ABL1—lung—acquired immunodeficiency syndrome	0.000132	0.0029	CbGeAlD
Regorafenib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.00013	0.00285	CbGeAlD
Regorafenib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000128	0.00281	CbGeAlD
Regorafenib—Connective tissue disorder—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.00153	CcSEcCtD
Regorafenib—Urethral disorder—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.00153	CcSEcCtD
Regorafenib—Tremor—Indinavir—acquired immunodeficiency syndrome	0.000123	0.00152	CcSEcCtD
Regorafenib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000122	0.00268	CbGeAlD
Regorafenib—Haemoglobin—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.00151	CcSEcCtD
Regorafenib—Hepatobiliary disease—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.00151	CcSEcCtD
Regorafenib—Haemorrhage—Saquinavir—acquired immunodeficiency syndrome	0.000121	0.0015	CcSEcCtD
Regorafenib—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000121	0.0015	CcSEcCtD
Regorafenib—KDR—brain—acquired immunodeficiency syndrome	0.000121	0.00266	CbGeAlD
Regorafenib—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000121	0.00149	CcSEcCtD
Regorafenib—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.000121	0.00149	CcSEcCtD
Regorafenib—Alopecia—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.00149	CcSEcCtD
Regorafenib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00012	0.00148	CcSEcCtD
Regorafenib—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.00148	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Erythema multiforme—Ritonavir—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000119	0.00147	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000119	0.00146	CcSEcCtD
Regorafenib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000118	0.00146	CcSEcCtD
Regorafenib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000118	0.00258	CbGeAlD
Regorafenib—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000118	0.00258	CbGeAlD
Regorafenib—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000117	0.00145	CcSEcCtD
Regorafenib—KDR—lymph node—acquired immunodeficiency syndrome	0.000117	0.00257	CbGeAlD
Regorafenib—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000117	0.00145	CcSEcCtD
Regorafenib—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.000116	0.00144	CcSEcCtD
Regorafenib—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000116	0.00143	CcSEcCtD
Regorafenib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000115	0.00142	CcSEcCtD
Regorafenib—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000115	0.00252	CbGeAlD
Regorafenib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000115	0.00142	CcSEcCtD
Regorafenib—Erythema multiforme—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.00142	CcSEcCtD
Regorafenib—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.00142	CcSEcCtD
Regorafenib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000115	0.00142	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000114	0.00141	CcSEcCtD
Regorafenib—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.00141	CcSEcCtD
Regorafenib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000114	0.00141	CcSEcCtD
Regorafenib—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.0014	CcSEcCtD
Regorafenib—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000114	0.0014	CcSEcCtD
Regorafenib—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.0014	CcSEcCtD
Regorafenib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000114	0.0014	CcSEcCtD
Regorafenib—Pain—Stavudine—acquired immunodeficiency syndrome	0.000113	0.0014	CcSEcCtD
Regorafenib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.0014	CcSEcCtD
Regorafenib—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000113	0.00139	CcSEcCtD
Regorafenib—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000113	0.00139	CcSEcCtD
Regorafenib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000113	0.00139	CcSEcCtD
Regorafenib—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000112	0.00139	CcSEcCtD
Regorafenib—CYP2C19—blood—acquired immunodeficiency syndrome	0.000112	0.00246	CbGeAlD
Regorafenib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000112	0.00138	CcSEcCtD
Regorafenib—Pain—Abacavir—acquired immunodeficiency syndrome	0.000112	0.00138	CcSEcCtD
Regorafenib—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000111	0.00137	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000111	0.00137	CcSEcCtD
Regorafenib—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.00136	CcSEcCtD
Regorafenib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.00136	CcSEcCtD
Regorafenib—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.00135	CcSEcCtD
Regorafenib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00011	0.00135	CcSEcCtD
Regorafenib—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000109	0.00135	CcSEcCtD
Regorafenib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.00135	CcSEcCtD
Regorafenib—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000109	0.00135	CcSEcCtD
Regorafenib—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000109	0.00134	CcSEcCtD
Regorafenib—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000109	0.00134	CcSEcCtD
Regorafenib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000109	0.00134	CcSEcCtD
Regorafenib—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000108	0.00134	CcSEcCtD
Regorafenib—KIT—brain—acquired immunodeficiency syndrome	0.000107	0.00236	CbGeAlD
Regorafenib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.00132	CcSEcCtD
Regorafenib—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.00132	CcSEcCtD
Regorafenib—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000107	0.00132	CcSEcCtD
Regorafenib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000106	0.00132	CcSEcCtD
Regorafenib—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.00131	CcSEcCtD
Regorafenib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.0013	CcSEcCtD
Regorafenib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000106	0.0013	CcSEcCtD
Regorafenib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000106	0.0013	CcSEcCtD
Regorafenib—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—PDGFRB—brain—acquired immunodeficiency syndrome	0.000105	0.0023	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.0013	CcSEcCtD
Regorafenib—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000105	0.00129	CcSEcCtD
Regorafenib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000105	0.00129	CcSEcCtD
Regorafenib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000104	0.00129	CcSEcCtD
Regorafenib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.00129	CcSEcCtD
Regorafenib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000104	0.00129	CcSEcCtD
Regorafenib—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000104	0.00228	CbGeAlD
Regorafenib—KIT—lymph node—acquired immunodeficiency syndrome	0.000104	0.00228	CbGeAlD
Regorafenib—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.00128	CcSEcCtD
Regorafenib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000103	0.00127	CcSEcCtD
Regorafenib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000103	0.00127	CcSEcCtD
Regorafenib—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.00127	CcSEcCtD
Regorafenib—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.00127	CcSEcCtD
Regorafenib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.00126	CcSEcCtD
Regorafenib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.00125	CcSEcCtD
Regorafenib—PDGFRB—lymph node—acquired immunodeficiency syndrome	0.000101	0.00222	CbGeAlD
Regorafenib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.00124	CcSEcCtD
Regorafenib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.0001	0.00124	CcSEcCtD
Regorafenib—Nausea—Amprenavir—acquired immunodeficiency syndrome	9.95e-05	0.00123	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	9.95e-05	0.00123	CcSEcCtD
Regorafenib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	9.93e-05	0.00123	CcSEcCtD
Regorafenib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	9.93e-05	0.00123	CcSEcCtD
Regorafenib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	9.91e-05	0.00122	CcSEcCtD
Regorafenib—Tremor—Saquinavir—acquired immunodeficiency syndrome	9.9e-05	0.00122	CcSEcCtD
Regorafenib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	9.88e-05	0.00122	CcSEcCtD
Regorafenib—Pain—Zidovudine—acquired immunodeficiency syndrome	9.85e-05	0.00122	CcSEcCtD
Regorafenib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	9.85e-05	0.00122	CcSEcCtD
Regorafenib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	9.83e-05	0.00121	CcSEcCtD
Regorafenib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	9.83e-05	0.00121	CcSEcCtD
Regorafenib—CYP2C8—blood—acquired immunodeficiency syndrome	9.77e-05	0.00214	CbGeAlD
Regorafenib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	9.76e-05	0.00121	CcSEcCtD
Regorafenib—Vomiting—Didanosine—acquired immunodeficiency syndrome	9.71e-05	0.0012	CcSEcCtD
Regorafenib—Rash—Didanosine—acquired immunodeficiency syndrome	9.63e-05	0.00119	CcSEcCtD
Regorafenib—Infection—Delavirdine—acquired immunodeficiency syndrome	9.62e-05	0.00119	CcSEcCtD
Regorafenib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	9.62e-05	0.00119	CcSEcCtD
Regorafenib—Headache—Didanosine—acquired immunodeficiency syndrome	9.57e-05	0.00118	CcSEcCtD
Regorafenib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	9.54e-05	0.00118	CcSEcCtD
Regorafenib—Asthenia—Stavudine—acquired immunodeficiency syndrome	9.51e-05	0.00117	CcSEcCtD
Regorafenib—ABCG2—blood—acquired immunodeficiency syndrome	9.5e-05	0.00208	CbGeAlD
Regorafenib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	9.48e-05	0.00117	CcSEcCtD
Regorafenib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	9.48e-05	0.00117	CcSEcCtD
Regorafenib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	9.46e-05	0.00117	CcSEcCtD
Regorafenib—Tremor—Lamivudine—acquired immunodeficiency syndrome	9.44e-05	0.00117	CcSEcCtD
Regorafenib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	9.42e-05	0.00116	CcSEcCtD
Regorafenib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	9.41e-05	0.00116	CcSEcCtD
Regorafenib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	9.39e-05	0.00116	CcSEcCtD
Regorafenib—Asthenia—Abacavir—acquired immunodeficiency syndrome	9.37e-05	0.00116	CcSEcCtD
Regorafenib—ABL1—brain—acquired immunodeficiency syndrome	9.35e-05	0.00205	CbGeAlD
Regorafenib—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	9.32e-05	0.00204	CbGeAlD
Regorafenib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	9.32e-05	0.00115	CcSEcCtD
Regorafenib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	9.32e-05	0.00115	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	9.28e-05	0.00115	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	9.25e-05	0.00114	CcSEcCtD
Regorafenib—Fatigue—Indinavir—acquired immunodeficiency syndrome	9.24e-05	0.00114	CcSEcCtD
Regorafenib—CYP2B6—digestive system—acquired immunodeficiency syndrome	9.2e-05	0.00202	CbGeAlD
Regorafenib—ABCG2—bone marrow—acquired immunodeficiency syndrome	9.19e-05	0.00202	CbGeAlD
Regorafenib—Pain—Indinavir—acquired immunodeficiency syndrome	9.16e-05	0.00113	CcSEcCtD
Regorafenib—ABCG2—spinal cord—acquired immunodeficiency syndrome	9.16e-05	0.00201	CbGeAlD
Regorafenib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	9.14e-05	0.00113	CcSEcCtD
Regorafenib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	9.12e-05	0.00113	CcSEcCtD
Regorafenib—CYP2C9—digestive system—acquired immunodeficiency syndrome	9.11e-05	0.002	CbGeAlD
Regorafenib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	9.11e-05	0.00112	CcSEcCtD
Regorafenib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	9.11e-05	0.00112	CcSEcCtD
Regorafenib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	9.1e-05	0.00112	CcSEcCtD
Regorafenib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	9.07e-05	0.00112	CcSEcCtD
Regorafenib—Nausea—Didanosine—acquired immunodeficiency syndrome	9.07e-05	0.00112	CcSEcCtD
Regorafenib—CYP2C8—vagina—acquired immunodeficiency syndrome	9.06e-05	0.00199	CbGeAlD
Regorafenib—ABL1—lymph node—acquired immunodeficiency syndrome	9.03e-05	0.00198	CbGeAlD
Regorafenib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	9.02e-05	0.00111	CcSEcCtD
Regorafenib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.94e-05	0.0011	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.0011	CcSEcCtD
Regorafenib—ABCG2—vagina—acquired immunodeficiency syndrome	8.81e-05	0.00193	CbGeAlD
Regorafenib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.8e-05	0.00109	CcSEcCtD
Regorafenib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.8e-05	0.00109	CcSEcCtD
Regorafenib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.79e-05	0.00108	CcSEcCtD
Regorafenib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.77e-05	0.00108	CcSEcCtD
Regorafenib—CYP2B6—blood—acquired immunodeficiency syndrome	8.77e-05	0.00192	CbGeAlD
Regorafenib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.76e-05	0.00108	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.74e-05	0.00108	CcSEcCtD
Regorafenib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.73e-05	0.00108	CcSEcCtD
Regorafenib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.73e-05	0.00108	CcSEcCtD
Regorafenib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.7e-05	0.00107	CcSEcCtD
Regorafenib—CYP2C9—blood—acquired immunodeficiency syndrome	8.68e-05	0.0019	CbGeAlD
Regorafenib—Pain—Efavirenz—acquired immunodeficiency syndrome	8.66e-05	0.00107	CcSEcCtD
Regorafenib—Rash—Nevirapine—acquired immunodeficiency syndrome	8.66e-05	0.00107	CcSEcCtD
Regorafenib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.65e-05	0.00107	CcSEcCtD
Regorafenib—Headache—Nevirapine—acquired immunodeficiency syndrome	8.6e-05	0.00106	CcSEcCtD
Regorafenib—Infection—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.00106	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.52e-05	0.00105	CcSEcCtD
Regorafenib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.47e-05	0.00105	CcSEcCtD
Regorafenib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.47e-05	0.00105	CcSEcCtD
Regorafenib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.46e-05	0.00104	CcSEcCtD
Regorafenib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.45e-05	0.00104	CcSEcCtD
Regorafenib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.44e-05	0.00104	CcSEcCtD
Regorafenib—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.43e-05	0.00104	CcSEcCtD
Regorafenib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.42e-05	0.00104	CcSEcCtD
Regorafenib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.39e-05	0.00104	CcSEcCtD
Regorafenib—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.38e-05	0.00104	CcSEcCtD
Regorafenib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.38e-05	0.00103	CcSEcCtD
Regorafenib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.37e-05	0.00103	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8.36e-05	0.00103	CcSEcCtD
Regorafenib—Rash—Stavudine—acquired immunodeficiency syndrome	8.36e-05	0.00103	CcSEcCtD
Regorafenib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.35e-05	0.00103	CcSEcCtD
Regorafenib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.35e-05	0.00103	CcSEcCtD
Regorafenib—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.33e-05	0.00103	CcSEcCtD
Regorafenib—ABCG2—lung—acquired immunodeficiency syndrome	8.33e-05	0.00183	CbGeAlD
Regorafenib—Headache—Stavudine—acquired immunodeficiency syndrome	8.3e-05	0.00103	CcSEcCtD
Regorafenib—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.3e-05	0.00103	CcSEcCtD
Regorafenib—Pain—Delavirdine—acquired immunodeficiency syndrome	8.28e-05	0.00102	CcSEcCtD
Regorafenib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	8.28e-05	0.00102	CcSEcCtD
Regorafenib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.27e-05	0.00102	CcSEcCtD
Regorafenib—Rash—Abacavir—acquired immunodeficiency syndrome	8.23e-05	0.00102	CcSEcCtD
Regorafenib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	8.23e-05	0.00102	CcSEcCtD
Regorafenib—Headache—Abacavir—acquired immunodeficiency syndrome	8.18e-05	0.00101	CcSEcCtD
Regorafenib—Infection—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.00101	CcSEcCtD
Regorafenib—Nausea—Nevirapine—acquired immunodeficiency syndrome	8.16e-05	0.00101	CcSEcCtD
Regorafenib—CYP2B6—vagina—acquired immunodeficiency syndrome	8.13e-05	0.00178	CbGeAlD
Regorafenib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	8.07e-05	0.000996	CcSEcCtD
Regorafenib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	8.05e-05	0.000995	CcSEcCtD
Regorafenib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	8e-05	0.000988	CcSEcCtD
Regorafenib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	8e-05	0.000988	CcSEcCtD
Regorafenib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.99e-05	0.000987	CcSEcCtD
Regorafenib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.92e-05	0.000978	CcSEcCtD
Regorafenib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.9e-05	0.000975	CcSEcCtD
Regorafenib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.88e-05	0.000974	CcSEcCtD
Regorafenib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.87e-05	0.000972	CcSEcCtD
Regorafenib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.79e-05	0.000962	CcSEcCtD
Regorafenib—Nausea—Abacavir—acquired immunodeficiency syndrome	7.76e-05	0.000958	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.73e-05	0.000955	CcSEcCtD
Regorafenib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.72e-05	0.000954	CcSEcCtD
Regorafenib—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.69e-05	0.000949	CcSEcCtD
Regorafenib—CYP2B6—lung—acquired immunodeficiency syndrome	7.69e-05	0.00169	CbGeAlD
Regorafenib—Pain—Ritonavir—acquired immunodeficiency syndrome	7.66e-05	0.000946	CcSEcCtD
Regorafenib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.66e-05	0.000946	CcSEcCtD
Regorafenib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.66e-05	0.000946	CcSEcCtD
Regorafenib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.5e-05	0.000926	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.44e-05	0.000919	CcSEcCtD
Regorafenib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.43e-05	0.000918	CcSEcCtD
Regorafenib—Pain—Saquinavir—acquired immunodeficiency syndrome	7.37e-05	0.000911	CcSEcCtD
Regorafenib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.33e-05	0.000905	CcSEcCtD
Regorafenib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.33e-05	0.000905	CcSEcCtD
Regorafenib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000905	CcSEcCtD
Regorafenib—Rash—Zidovudine—acquired immunodeficiency syndrome	7.27e-05	0.000897	CcSEcCtD
Regorafenib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.26e-05	0.000897	CcSEcCtD
Regorafenib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.26e-05	0.000896	CcSEcCtD
Regorafenib—Headache—Zidovudine—acquired immunodeficiency syndrome	7.22e-05	0.000891	CcSEcCtD
Regorafenib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	7.15e-05	0.000883	CcSEcCtD
Regorafenib—CYP2B6—nervous system—acquired immunodeficiency syndrome	7.12e-05	0.00156	CbGeAlD
Regorafenib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	7.1e-05	0.000877	CcSEcCtD
Regorafenib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	7.09e-05	0.000876	CcSEcCtD
Regorafenib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	7.08e-05	0.000874	CcSEcCtD
Regorafenib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	7.08e-05	0.000874	CcSEcCtD
Regorafenib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000871	CcSEcCtD
Regorafenib—Pain—Lamivudine—acquired immunodeficiency syndrome	7.03e-05	0.000869	CcSEcCtD
Regorafenib—ABCB1—retina—acquired immunodeficiency syndrome	7e-05	0.00154	CbGeAlD
Regorafenib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.95e-05	0.000858	CcSEcCtD
Regorafenib—CYP3A4—digestive system—acquired immunodeficiency syndrome	6.95e-05	0.00152	CbGeAlD
Regorafenib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.93e-05	0.000855	CcSEcCtD
Regorafenib—CYP2B6—central nervous system—acquired immunodeficiency syndrome	6.85e-05	0.0015	CbGeAlD
Regorafenib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.84e-05	0.000845	CcSEcCtD
Regorafenib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.82e-05	0.000842	CcSEcCtD
Regorafenib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.82e-05	0.000842	CcSEcCtD
Regorafenib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.81e-05	0.000841	CcSEcCtD
Regorafenib—Rash—Indinavir—acquired immunodeficiency syndrome	6.76e-05	0.000834	CcSEcCtD
Regorafenib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.75e-05	0.000834	CcSEcCtD
Regorafenib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000831	CcSEcCtD
Regorafenib—Headache—Indinavir—acquired immunodeficiency syndrome	6.71e-05	0.000829	CcSEcCtD
Regorafenib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.63e-05	0.000818	CcSEcCtD
Regorafenib—CYP3A4—blood—acquired immunodeficiency syndrome	6.62e-05	0.00145	CbGeAlD
Regorafenib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.5e-05	0.000803	CcSEcCtD
Regorafenib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.5e-05	0.000803	CcSEcCtD
Regorafenib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.44e-05	0.000795	CcSEcCtD
Regorafenib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.43e-05	0.000794	CcSEcCtD
Regorafenib—Rash—Efavirenz—acquired immunodeficiency syndrome	6.38e-05	0.000788	CcSEcCtD
Regorafenib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.38e-05	0.000788	CcSEcCtD
Regorafenib—Nausea—Indinavir—acquired immunodeficiency syndrome	6.37e-05	0.000786	CcSEcCtD
Regorafenib—Headache—Efavirenz—acquired immunodeficiency syndrome	6.34e-05	0.000783	CcSEcCtD
Regorafenib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.000764	CcSEcCtD
Regorafenib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6.16e-05	0.000761	CcSEcCtD
Regorafenib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.13e-05	0.000757	CcSEcCtD
Regorafenib—Rash—Delavirdine—acquired immunodeficiency syndrome	6.11e-05	0.000754	CcSEcCtD
Regorafenib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.1e-05	0.000754	CcSEcCtD
Regorafenib—Headache—Delavirdine—acquired immunodeficiency syndrome	6.07e-05	0.000749	CcSEcCtD
Regorafenib—CYP2C8—brain—acquired immunodeficiency syndrome	6.06e-05	0.00133	CbGeAlD
Regorafenib—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.01e-05	0.000743	CcSEcCtD
Regorafenib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.9e-05	0.000729	CcSEcCtD
Regorafenib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.9e-05	0.000729	CcSEcCtD
Regorafenib—ABCG2—brain—acquired immunodeficiency syndrome	5.9e-05	0.00129	CbGeAlD
Regorafenib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.75e-05	0.000711	CcSEcCtD
Regorafenib—ABCG2—lymph node—acquired immunodeficiency syndrome	5.7e-05	0.00125	CbGeAlD
Regorafenib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.7e-05	0.000703	CcSEcCtD
Regorafenib—Rash—Ritonavir—acquired immunodeficiency syndrome	5.65e-05	0.000697	CcSEcCtD
Regorafenib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.64e-05	0.000697	CcSEcCtD
Regorafenib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.63e-05	0.000695	CcSEcCtD
Regorafenib—Headache—Ritonavir—acquired immunodeficiency syndrome	5.61e-05	0.000693	CcSEcCtD
Regorafenib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.48e-05	0.000677	CcSEcCtD
Regorafenib—CYP2B6—brain—acquired immunodeficiency syndrome	5.44e-05	0.00119	CbGeAlD
Regorafenib—Rash—Saquinavir—acquired immunodeficiency syndrome	5.44e-05	0.000671	CcSEcCtD
Regorafenib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.43e-05	0.000671	CcSEcCtD
Regorafenib—Headache—Saquinavir—acquired immunodeficiency syndrome	5.4e-05	0.000667	CcSEcCtD
Regorafenib—CYP3A4—nervous system—acquired immunodeficiency syndrome	5.37e-05	0.00118	CbGeAlD
Regorafenib—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.32e-05	0.000657	CcSEcCtD
Regorafenib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.23e-05	0.000646	CcSEcCtD
Regorafenib—Rash—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.00064	CcSEcCtD
Regorafenib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.18e-05	0.00064	CcSEcCtD
Regorafenib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	5.17e-05	0.00113	CbGeAlD
Regorafenib—Headache—Lamivudine—acquired immunodeficiency syndrome	5.15e-05	0.000636	CcSEcCtD
Regorafenib—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.12e-05	0.000632	CcSEcCtD
Regorafenib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	4.98e-05	0.00109	CbGeAlD
Regorafenib—ABCB1—digestive system—acquired immunodeficiency syndrome	4.92e-05	0.00108	CbGeAlD
Regorafenib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000603	CcSEcCtD
Regorafenib—ABCB1—blood—acquired immunodeficiency syndrome	4.69e-05	0.00103	CbGeAlD
Regorafenib—ABCB1—bone marrow—acquired immunodeficiency syndrome	4.53e-05	0.000995	CbGeAlD
Regorafenib—ABCB1—spinal cord—acquired immunodeficiency syndrome	4.51e-05	0.00099	CbGeAlD
Regorafenib—ABCB1—vagina—acquired immunodeficiency syndrome	4.34e-05	0.000953	CbGeAlD
Regorafenib—ABCB1—lung—acquired immunodeficiency syndrome	4.11e-05	0.000901	CbGeAlD
Regorafenib—ABCB1—nervous system—acquired immunodeficiency syndrome	3.8e-05	0.000834	CbGeAlD
Regorafenib—ABCB1—central nervous system—acquired immunodeficiency syndrome	3.66e-05	0.000803	CbGeAlD
Regorafenib—ABCB1—brain—acquired immunodeficiency syndrome	2.91e-05	0.000638	CbGeAlD
Regorafenib—ABCB1—lymph node—acquired immunodeficiency syndrome	2.81e-05	0.000616	CbGeAlD
Regorafenib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.06e-05	0.000406	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.06e-05	0.000405	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.06e-05	0.000405	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.06e-05	0.000405	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD79A—acquired immunodeficiency syndrome	1.06e-05	0.000404	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD40LG—acquired immunodeficiency syndrome	1.05e-05	0.000404	CbGpPWpGaD
Regorafenib—BRAF—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000403	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000402	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1.04e-05	0.0004	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CSF2—acquired immunodeficiency syndrome	1.04e-05	0.000399	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD8A—acquired immunodeficiency syndrome	1.04e-05	0.000399	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.04e-05	0.000399	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.04e-05	0.000398	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD40LG—acquired immunodeficiency syndrome	1.03e-05	0.000396	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	1.03e-05	0.000396	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.03e-05	0.000395	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.03e-05	0.000394	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD8A—acquired immunodeficiency syndrome	1.02e-05	0.000392	CbGpPWpGaD
Regorafenib—KIT—Immune System—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000392	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.01e-05	0.000387	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HLA-B—acquired immunodeficiency syndrome	1e-05	0.000384	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNA1—acquired immunodeficiency syndrome	9.94e-06	0.000381	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	9.9e-06	0.000379	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—TNF—acquired immunodeficiency syndrome	9.88e-06	0.000378	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.87e-06	0.000378	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.85e-06	0.000377	CbGpPWpGaD
Regorafenib—KIT—Immune System—HLA-B—acquired immunodeficiency syndrome	9.84e-06	0.000377	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.83e-06	0.000376	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD40LG—acquired immunodeficiency syndrome	9.82e-06	0.000376	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD40LG—acquired immunodeficiency syndrome	9.8e-06	0.000375	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.79e-06	0.000375	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.79e-06	0.000375	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.74e-06	0.000373	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD8A—acquired immunodeficiency syndrome	9.71e-06	0.000372	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CSF2—acquired immunodeficiency syndrome	9.71e-06	0.000372	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.7e-06	0.000372	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.7e-06	0.000372	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.69e-06	0.000371	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	9.69e-06	0.000371	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	9.69e-06	0.000371	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—ALB—acquired immunodeficiency syndrome	9.67e-06	0.00037	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD79A—acquired immunodeficiency syndrome	9.65e-06	0.00037	CbGpPWpGaD
Regorafenib—RAF1—Disease—CXCR4—acquired immunodeficiency syndrome	9.58e-06	0.000367	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.58e-06	0.000367	CbGpPWpGaD
Regorafenib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.57e-06	0.000367	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.56e-06	0.000366	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	9.55e-06	0.000366	CbGpPWpGaD
Regorafenib—BRAF—Disease—CCR5—acquired immunodeficiency syndrome	9.49e-06	0.000364	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	9.46e-06	0.000362	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.39e-06	0.00036	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HLA-B—acquired immunodeficiency syndrome	9.34e-06	0.000358	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	9.32e-06	0.000357	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	9.23e-06	0.000354	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.2e-06	0.000352	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	9.17e-06	0.000351	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.17e-06	0.000351	CbGpPWpGaD
Regorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.14e-06	0.00035	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.08e-06	0.000348	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.08e-06	0.000348	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	9.06e-06	0.000347	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.05e-06	0.000347	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.03e-06	0.000346	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	9.01e-06	0.000345	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.99e-06	0.000344	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.99e-06	0.000344	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.91e-06	0.000341	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.89e-06	0.00034	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.86e-06	0.000339	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.83e-06	0.000338	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.83e-06	0.000338	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD40LG—acquired immunodeficiency syndrome	8.83e-06	0.000338	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CCR5—acquired immunodeficiency syndrome	8.8e-06	0.000337	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CSF2—acquired immunodeficiency syndrome	8.73e-06	0.000334	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD8A—acquired immunodeficiency syndrome	8.73e-06	0.000334	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	8.66e-06	0.000332	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.64e-06	0.000331	CbGpPWpGaD
Regorafenib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	8.64e-06	0.000331	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—CD4—acquired immunodeficiency syndrome	8.61e-06	0.00033	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	8.6e-06	0.000329	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	8.57e-06	0.000328	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	8.53e-06	0.000327	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.51e-06	0.000326	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	8.5e-06	0.000326	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	8.5e-06	0.000326	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—TNF—acquired immunodeficiency syndrome	8.49e-06	0.000325	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	8.42e-06	0.000322	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HLA-B—acquired immunodeficiency syndrome	8.4e-06	0.000322	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	8.39e-06	0.000321	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.38e-06	0.000321	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.38e-06	0.000321	CbGpPWpGaD
Regorafenib—RAF1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.37e-06	0.000321	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.36e-06	0.00032	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.36e-06	0.00032	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	8.26e-06	0.000317	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.26e-06	0.000316	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—IL6—acquired immunodeficiency syndrome	8.22e-06	0.000315	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CCR5—acquired immunodeficiency syndrome	8.2e-06	0.000314	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	8.18e-06	0.000313	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	8.18e-06	0.000313	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—IL6—acquired immunodeficiency syndrome	8.16e-06	0.000313	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.01e-06	0.000307	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—IL6—acquired immunodeficiency syndrome	7.97e-06	0.000305	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.89e-06	0.000302	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD40LG—acquired immunodeficiency syndrome	7.87e-06	0.000301	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—IL2—acquired immunodeficiency syndrome	7.84e-06	0.0003	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.8e-06	0.000299	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.79e-06	0.000298	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CSF2—acquired immunodeficiency syndrome	7.78e-06	0.000298	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD8A—acquired immunodeficiency syndrome	7.78e-06	0.000298	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.67e-06	0.000294	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.53e-06	0.000288	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.53e-06	0.000288	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HLA-B—acquired immunodeficiency syndrome	7.48e-06	0.000287	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.45e-06	0.000285	CbGpPWpGaD
Regorafenib—RAF1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	7.4e-06	0.000283	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.38e-06	0.000283	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CCR5—acquired immunodeficiency syndrome	7.37e-06	0.000282	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.37e-06	0.000282	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.34e-06	0.000281	CbGpPWpGaD
Regorafenib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.3e-06	0.00028	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	7.27e-06	0.000279	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.27e-06	0.000278	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—TNF—acquired immunodeficiency syndrome	7.27e-06	0.000278	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	7.2e-06	0.000276	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.14e-06	0.000273	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—IL6—acquired immunodeficiency syndrome	6.85e-06	0.000262	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.84e-06	0.000262	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.78e-06	0.00026	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IFNG—acquired immunodeficiency syndrome	6.75e-06	0.000259	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.74e-06	0.000258	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.72e-06	0.000257	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.71e-06	0.000257	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.71e-06	0.000257	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.71e-06	0.000257	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.65e-06	0.000255	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.62e-06	0.000253	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—IL6—acquired immunodeficiency syndrome	6.58e-06	0.000252	CbGpPWpGaD
Regorafenib—RAF1—Disease—CCR5—acquired immunodeficiency syndrome	6.57e-06	0.000252	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.53e-06	0.00025	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—CD4—acquired immunodeficiency syndrome	6.52e-06	0.00025	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.37e-06	0.000244	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	6.36e-06	0.000244	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.36e-06	0.000244	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.28e-06	0.000241	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.26e-06	0.00024	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IFNG—acquired immunodeficiency syndrome	6.2e-06	0.000237	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.16e-06	0.000236	CbGpPWpGaD
Regorafenib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	6.09e-06	0.000233	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—IL6—acquired immunodeficiency syndrome	6.05e-06	0.000232	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.05e-06	0.000232	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL2—acquired immunodeficiency syndrome	6e-06	0.00023	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—CD4—acquired immunodeficiency syndrome	5.98e-06	0.000229	CbGpPWpGaD
Regorafenib—BRAF—Disease—CD4—acquired immunodeficiency syndrome	5.96e-06	0.000228	CbGpPWpGaD
Regorafenib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	5.88e-06	0.000225	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.87e-06	0.000225	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.86e-06	0.000225	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.82e-06	0.000223	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IFNG—acquired immunodeficiency syndrome	5.78e-06	0.000221	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	5.76e-06	0.000221	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.74e-06	0.00022	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.73e-06	0.000219	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.73e-06	0.000219	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.64e-06	0.000216	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—CD4—acquired immunodeficiency syndrome	5.58e-06	0.000214	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	5.56e-06	0.000213	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.56e-06	0.000213	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.55e-06	0.000213	CbGpPWpGaD
Regorafenib—FGFR2—Disease—CD4—acquired immunodeficiency syndrome	5.53e-06	0.000212	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL2—acquired immunodeficiency syndrome	5.51e-06	0.000211	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.46e-06	0.000209	CbGpPWpGaD
Regorafenib—KIT—Disease—CD4—acquired immunodeficiency syndrome	5.43e-06	0.000208	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	5.41e-06	0.000207	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.34e-06	0.000205	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IFNG—acquired immunodeficiency syndrome	5.19e-06	0.000199	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.18e-06	0.000198	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	5.17e-06	0.000198	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.16e-06	0.000198	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CD4—acquired immunodeficiency syndrome	5.15e-06	0.000197	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	5.14e-06	0.000197	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.14e-06	0.000197	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL2—acquired immunodeficiency syndrome	5.13e-06	0.000197	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	5.12e-06	0.000196	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.11e-06	0.000196	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	5.06e-06	0.000194	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.03e-06	0.000193	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CD4—acquired immunodeficiency syndrome	5.01e-06	0.000192	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	4.88e-06	0.000187	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.77e-06	0.000183	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.76e-06	0.000182	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.7e-06	0.00018	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.65e-06	0.000178	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CD4—acquired immunodeficiency syndrome	4.63e-06	0.000177	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IFNG—acquired immunodeficiency syndrome	4.63e-06	0.000177	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2—acquired immunodeficiency syndrome	4.61e-06	0.000177	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.6e-06	0.000176	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.54e-06	0.000174	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.51e-06	0.000173	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.5e-06	0.000172	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	4.49e-06	0.000172	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CD4—acquired immunodeficiency syndrome	4.47e-06	0.000171	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.25e-06	0.000163	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—IL6—acquired immunodeficiency syndrome	4.15e-06	0.000159	CbGpPWpGaD
Regorafenib—RAF1—Disease—CD4—acquired immunodeficiency syndrome	4.12e-06	0.000158	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2—acquired immunodeficiency syndrome	4.11e-06	0.000157	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	4.03e-06	0.000154	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	4.03e-06	0.000154	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.98e-06	0.000153	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.95e-06	0.000151	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.88e-06	0.000149	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.88e-06	0.000149	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.84e-06	0.000147	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.56e-06	0.000136	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—IL6—acquired immunodeficiency syndrome	3.53e-06	0.000135	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.5e-06	0.000134	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	3.42e-06	0.000131	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.32e-06	0.000127	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.31e-06	0.000127	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—IL6—acquired immunodeficiency syndrome	3.24e-06	0.000124	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—acquired immunodeficiency syndrome	3.22e-06	0.000123	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	3.18e-06	0.000122	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—acquired immunodeficiency syndrome	3.02e-06	0.000116	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	3.01e-06	0.000115	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—acquired immunodeficiency syndrome	2.99e-06	0.000114	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.98e-06	0.000114	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—acquired immunodeficiency syndrome	2.93e-06	0.000112	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.8e-06	0.000107	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—acquired immunodeficiency syndrome	2.79e-06	0.000107	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	2.78e-06	0.000106	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—acquired immunodeficiency syndrome	2.71e-06	0.000104	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.66e-06	0.000102	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.65e-06	0.000102	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.64e-06	0.000101	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	2.64e-06	0.000101	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	2.51e-06	9.6e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—acquired immunodeficiency syndrome	2.5e-06	9.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—acquired immunodeficiency syndrome	2.42e-06	9.25e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.28e-06	8.73e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.26e-06	8.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—acquired immunodeficiency syndrome	2.23e-06	8.54e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	2.12e-06	8.13e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.09e-06	8.02e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.06e-06	7.87e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.95e-06	7.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.95e-06	7.45e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.89e-06	7.25e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.85e-06	7.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.75e-06	6.71e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	1.73e-06	6.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.56e-06	5.98e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.14e-06	4.36e-05	CbGpPWpGaD
